Thiazolidinediones (TZDs)

Thiazolidinediones (TZDs) — pioglitazone and rosiglitazone — are USMLE Step 1-tested insulin sensitizers that students consistently conflate with secretagogues like sulfonylureas. TZDs act through PPAR-gamma agonism in adipose tissue and have no effect on pancreatic insulin release — a distinction the exam exploits by asking which drugs cause hypoglycemia. Step 1 tests this class from two main angles: the mechanism (PPAR-gamma, insulin sensitization, not secretagogue) and the adverse effect profile (fluid retention, heart failure exacerbation, and fractures). If you can keep those two angles crisp and distinct from other antidiabetic mechanisms, you're most of the way there.

The tricky part is that TZDs sit in a crowded pharmacology space alongside drugs that DO stimulate the pancreas (sulfonylureas, GLP-1 agonists, etc.), so confusing the mechanism is easy under pressure. The exam will often give you a scenario — a patient with T2DM develops new-onset edema or worsening heart failure — and you need to recognize TZD-induced sodium/water retention as the culprit. That mechanism is specific: PPAR-gamma activation in the renal collecting duct increases ENaC-mediated sodium reabsorption. It's not nephrotoxicity, and it's not just a vague side effect to memorize.

The fracture risk angle is one students routinely miss. USMLE Step 1 can present a patient on pioglitazone with unexpected fractures, and the mechanism — PPAR-gamma shifting mesenchymal stem cells toward adipocytes instead of osteoblasts — ties the adverse effect directly back to the drug's core mechanism. That's the kind of connection the exam rewards. Don't just memorize 'TZDs cause fractures'; know why, and know it's especially prominent in women.